The 25% rise in the traditional Chinese medicine index this year reflects the mismatch between supply and demand, and the increase in investment by drugmakers has triggered this round of price increases. The company covers the whole industry chain of "cultivation of Chinese herbal medicines + trade of medicinal materials + proprietary Chinese medicines + prepared slices of traditional Chinese medicine" and has several hundred million yuan of single products. the completion of the mixed reform is expected to further integrate resources and improve marketing efficiency.